Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2011

01.05.2011

Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis

verfasst von: Shaheeda Ahmed, C. Michael Gibson, Christopher P. Cannon, Sabina A. Murphy, Marc S. Sabatine

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Reduced glomerular filtration rate (GFR) is associated with adverse outcomes in patients with cardiovascular disease. We explored the relationship between GFR and angiographic and clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients receiving pharamacologic reperfusion, with or without clopidogrel. Data were available to estimate GFR in 3,252 STEMI patients undergoing fibrinolysis, randomized to clopidogrel versus placebo in the CLARITY-TIMI 28 trial. Patients with a creatinine > 2.5 mg/dl were excluded from the trial. We compared outcomes between patients with no, mild or moderate reductions in baseline estimated GFR (ml/min/1.73 m2) of ≥90, 60–89, and <60, respectively. Compared to patients with no (n = 841) or mildly reduced GFR (n = 1897), those with moderately reduced GFR (n = 514) were older, more often female, and were more likely to have diabetes and hypertension (P ≤ 0.001 for all). The risk of the primary endpoint (an occluded infarct-related artery on angiography or death/myocardial infarction by day 8), 30 day cardiovascular events (death, myocardial infarction, or urgent revascularization for recurrent ischemia) and 30 day Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding increased as GFR declined (P for trend 0.003, <0.0001, and 0.0008 respectively). The adjusted risk of 30 day ischemic complications remained higher in patients with moderately reduced versus normal GFR (OR 1.5, 95% CI 1.0−2.1, P = 0.04). Treatment with clopidogrel tended to yield greater benefit in patients with normal or mildly reduced GFR versus in patients with moderately reduced GFR. In conclusion, STEMI patients with reduced GFR treated with medical reperfusion, including dual antiplatelet therapy, have higher rates of adverse clinical outcome. Further research on optimal STEMI therapy in this high-risk group is warranted.
Literatur
1.
Zurück zum Zitat Anavekar NS, McMurray JJ, Velazquez EJ et al (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351(13):1285–1295PubMedCrossRef Anavekar NS, McMurray JJ, Velazquez EJ et al (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351(13):1285–1295PubMedCrossRef
2.
Zurück zum Zitat Gibson CM, Pinto DS, Murphy SA et al (2003) Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 42(9):1535–1543PubMedCrossRef Gibson CM, Pinto DS, Murphy SA et al (2003) Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 42(9):1535–1543PubMedCrossRef
3.
Zurück zum Zitat Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30(5):579–589PubMedCrossRef Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30(5):579–589PubMedCrossRef
4.
Zurück zum Zitat Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK (1994) Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5(1):36–46PubMed Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK (1994) Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5(1):36–46PubMed
5.
Zurück zum Zitat Sagripanti A, Barsotti G (1997) Bleeding and thrombosis in chronic uremia. Nephron 75(2):125–139PubMedCrossRef Sagripanti A, Barsotti G (1997) Bleeding and thrombosis in chronic uremia. Nephron 75(2):125–139PubMedCrossRef
6.
Zurück zum Zitat Gibson CM, Dumaine RL, Gelfand EV et al (2004) Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13, 307 patients in five TIMI trials. Eur Heart J 25(22):1998–2005PubMedCrossRef Gibson CM, Dumaine RL, Gelfand EV et al (2004) Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13, 307 patients in five TIMI trials. Eur Heart J 25(22):1998–2005PubMedCrossRef
7.
Zurück zum Zitat Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA (2003) Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41(5):718–724PubMedCrossRef Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA (2003) Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41(5):718–724PubMedCrossRef
8.
Zurück zum Zitat Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179–1189PubMedCrossRef Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179–1189PubMedCrossRef
9.
Zurück zum Zitat Sabatine MS, McCabe CH, Gibson CM, Cannon CP (2005) Design and rationale of clopidogrel as adjunctive reperfusion therapy-thrombolysis in myocardial infarction (CLARITY-TIMI) 28 trial. Am Heart J 149(2):227–233PubMedCrossRef Sabatine MS, McCabe CH, Gibson CM, Cannon CP (2005) Design and rationale of clopidogrel as adjunctive reperfusion therapy-thrombolysis in myocardial infarction (CLARITY-TIMI) 28 trial. Am Heart J 149(2):227–233PubMedCrossRef
10.
Zurück zum Zitat K/DOQI (2002) Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1):S1-266 K/DOQI (2002) Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1):S1-266
11.
Zurück zum Zitat Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147PubMed Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147PubMed
12.
Zurück zum Zitat Al Suwaidi J, Reddan DN, Williams K et al (2002) Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106(8):974–980PubMedCrossRef Al Suwaidi J, Reddan DN, Williams K et al (2002) Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106(8):974–980PubMedCrossRef
13.
Zurück zum Zitat Angiolillo DJ, Bernardo E, Capodanno D et al (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55(11):1139–46PubMedCrossRef Angiolillo DJ, Bernardo E, Capodanno D et al (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55(11):1139–46PubMedCrossRef
14.
Zurück zum Zitat Angiolillo DJ, Bernardo E, Sabate M et al (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50(16):1541–1547PubMedCrossRef Angiolillo DJ, Bernardo E, Sabate M et al (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50(16):1541–1547PubMedCrossRef
15.
Zurück zum Zitat Kirtane AJ, Vafai JJ, Murphy SA et al (2006) Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J 27(17):2040–2045PubMedCrossRef Kirtane AJ, Vafai JJ, Murphy SA et al (2006) Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J 27(17):2040–2045PubMedCrossRef
16.
Zurück zum Zitat Appelbaum E, Kirtane AJ, Clark A et al (2009) Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. J Thromb Thrombolysis 27(2):123–129PubMedCrossRef Appelbaum E, Kirtane AJ, Clark A et al (2009) Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. J Thromb Thrombolysis 27(2):123–129PubMedCrossRef
17.
Zurück zum Zitat Gibson CM, Cannon CP, Murphy SA et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101(2):125–130PubMed Gibson CM, Cannon CP, Murphy SA et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101(2):125–130PubMed
18.
Zurück zum Zitat Keltai M, Tonelli M, Mann JF et al (2007) Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14(2):312–318PubMedCrossRef Keltai M, Tonelli M, Mann JF et al (2007) Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14(2):312–318PubMedCrossRef
19.
Zurück zum Zitat Gibson CM, Pride YB, Frederick PD et al (2008) Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 156(6):1035–1044PubMedCrossRef Gibson CM, Pride YB, Frederick PD et al (2008) Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 156(6):1035–1044PubMedCrossRef
20.
Zurück zum Zitat Widimsky P, Wijns W, Fajadet J et al (2010) Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 31(8):943–57PubMedCrossRef Widimsky P, Wijns W, Fajadet J et al (2010) Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 31(8):943–57PubMedCrossRef
21.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108(17):2154–2169PubMedCrossRef Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108(17):2154–2169PubMedCrossRef
Metadaten
Titel
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis
verfasst von
Shaheeda Ahmed
C. Michael Gibson
Christopher P. Cannon
Sabina A. Murphy
Marc S. Sabatine
Publikationsdatum
01.05.2011
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2011
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-011-0566-9

Weitere Artikel der Ausgabe 4/2011

Journal of Thrombosis and Thrombolysis 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.